Format

Send to

Choose Destination
Pract Neurol. 2015 Jun;15(3):199-206. doi: 10.1136/practneurol-2015-001126.

Myasthenia gravis: Association of British Neurologists' management guidelines.

Author information

1
Department of Neurology, Greater Manchester Neuroscience Centre, Salford, Greater Manchester, UK.
2
Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK.
3
Department of Neurology, Nottingham University Hospitals NHS Trust, Queens Medical Centre,Nottingham, Nottinghamshire, UK.
4
Department of Neurology, Morriston Hospital, Swansea, Wales, UK.
5
Department of Neurology, John Radcliffe Hospital, Oxford, UK.

Abstract

Myasthenia gravis is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence based medicine. The basic principles of treatment are well known, however, patients continue to receive suboptimal treatment as a result of which a myasthenia gravis guidelines group was established under the aegis of The Association of British Neurologists. These guidelines attempt to steer a path between evidence-based practice where available, and established best practice where evidence is unavailable. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians not just in using the right treatments in the right order, but in optimising the use of well-known therapeutic agents. Clinical practice can be audited against these guidelines.

KEYWORDS:

MYASTHENIA

PMID:
25977271
DOI:
10.1136/practneurol-2015-001126
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center